

Pharmacy Management Drug Policy

SUBJECT: Papzimeos™ (zopapogene imadenovec-drba) POLICY NUMBER: PHARMACY-140 EFFECTIVE DATE: 01/2026 LAST REVIEW DATE: 06/12/2026		
<i>If the member's subscriber contract excludes coverage for a specific service or prescription drug, it is not covered under that contract. In such cases, medical or drug policy criteria are not applied. This drug policy applies to the following line/s of business:</i>		
Policy Application		
Category:	<input checked="" type="checkbox"/> Commercial Group (e.g., EPO, HMO, POS, PPO)	<input checked="" type="checkbox"/> Medicare Advantage
	<input checked="" type="checkbox"/> On Exchange Qualified Health Plans (QHP)	<input type="checkbox"/> Medicare Part D
	<input checked="" type="checkbox"/> Off Exchange Direct Pay	<input checked="" type="checkbox"/> Essential Plan (EP)
	<input checked="" type="checkbox"/> Medicaid & Health and Recovery Plans (MMC/HARP)	<input checked="" type="checkbox"/> Child Health Plus (CHP)
	<input type="checkbox"/> Federal Employee Program (FEP)	<input type="checkbox"/> Ancillary Services
	<input checked="" type="checkbox"/> Dual Eligible Special Needs Plan (D-SNP)	

DESCRIPTION:

Papzimeos™ (zopapogene imadenovec-drba) is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of adults with recurrent respiratory papillomatosis. The recommended dose of Papzimeos is 5 x 10¹¹ particle units (PU) per injection and is administered via subcutaneous injection four (4) times over a 12-week interval, with doses given on Day 1, Week 2, Week 6 and Week 12. Surgical debulking of visible papilloma should be performed prior to the initial administration of Papzimeos. To maintain minimal residual disease during treatment, visible papilloma should be removed, if present, prior to the third and fourth administration of Papzimeos.

Papzimeos is a non-replicating adenoviral vector-based immunotherapy designed to express a fusion antigen of selected regions of human papillomavirus (HPV) proteins expressed in HPV 6- and HPV 11-infected cells. Papzimeos is designed to generate an immune response directed against HPV 6 and HPV 11 proteins in patients with recurrent respiratory papillomatosis.

Recurrent respiratory papillomatosis (RRP) is a rare disease in which benign (noncancerous) tumors called papillomas grow in the air passages leading from the nose and mouth into the lungs (respiratory tract). Although the tumors can grow anywhere in the respiratory tract, they most often affect the larynx and vocal cords - a condition called laryngeal papillomatosis. RRP is caused by the human papilloma virus (HPV). Two specific subtypes, HPV 6 and HPV 11, account for more than 90% of cases of RRP.⁴ Surgical debulking of the papillomas is the standard treatment, however once the tumors have been removed, they often grow back. It is common for patients to require multiple surgeries during their lifetime. About 20% of patients with RRP require adjunctive medical treatment in addition to surgery to control the disease.⁵ The most common symptom is hoarseness, although patients can also experience difficulties speaking and breathing due to airway obstruction. The specific symptoms, course of the disease, and severity of RRP can vary greatly from one person to another. Although rare, RRP can lead to dysplasia and malignant transformation in about 15% of patients.⁶

Papzimeos was FDA-approved on August 14, 2025. The efficacy of Papzimeos was evaluated in a single-arm, phase I/II trial of adult patients aged 18 years or older with RRP who required three or more surgical debulking procedures in the 1 year before treatment [NCT04724980]. Thirty-eight (38) patients received Papzimeos on Day 1 following surgical debulking of disease, and on Days 15, 43,

Pharmacy Management Drug Policy

Papzimeos™ (zopapogene imadenovec-drba)

and 85. The primary outcome measure was complete response rate, defined as the percentage of patients who did not require an intervention to control RRP in the 12 months after treatment. A total of thirty-five (35) patients were treated at a dose of 5×10^{11} PU and were included in the efficacy evaluation. Eighteen of the thirty-five patients achieved a complete response at 12 months resulting in a complete response rate of 51% [95% confidence interval (CI) 34 to 69%]. Among the eighteen patients with a complete response in the ongoing study, 15 maintained a complete response at 24 months yielding a complete response rate of 43% (95% CI 26 to 61%) at 2 years. Adverse events were mild and included injection site reactions, fatigue, chills, and fever.

POLICY:

Papzimeos (zopapogene imadenovec-drba) - Medical

1. Patient must be ≥ 18 years of age **AND**
2. Must be prescribed by, or in consultation with, a board-certified otolaryngologist (ENT), laryngologist, or head and neck surgical oncologist experienced in the management of recurrent respiratory papillomatosis (RRP) **AND**
3. Must have a diagnosis of histologically confirmed laryngotracheal recurrent respiratory papillomatosis (RRP) **AND**
4. Must have HPV serotype 6 or 11 positivity documented by polymerase chain reaction/in situ hybridization (PCR/ISH) from airway lesions
 - a. Archival tissue obtained from prior surgical debulking procedures is acceptable provided that the sample is representative of the current disease site and histology. Additionally, there must be no indication of a non-HPV-driven or transformed malignancy.
5. Documentation of eligible disease severity and prior treatment history must meet ONE of the following (a or b):
 - a. ≥ 3 surgical interventions in the prior 12 months **OR**
 - b. ≥ 2 surgical interventions in the prior 12 months with at least one of the following:
 - i. Extensive anatomic involvement, such as multi-site laryngotracheal disease, pulmonary spread, or a Derkay total score ≥ 20 (or equivalent qualitative description of high burden)
 - ii. Rapid recurrence requiring repeat surgery or visible regrowth within ≤ 12 weeks of prior debulking
 - iii. Documentation of clinically significant functional impairment, confirmed by the treating ENT, as evidenced by:
 1. Airway compromise, such as, stridor, dyspnea, respiratory distress, or direct visualization of airway obstruction on laryngoscopy or bronchoscopy
 2. Severe dysphonia or voice dysfunction, supported by Voice Handicap Index (VHI-10) score in the severe range or equivalent
6. Papzimeos is indicated for a one-time treatment cycle of 4 doses and therefore will not be authorized for retreatment. Retreatment will be considered experimental/investigational when any FDA approved gene therapy, or any other gene therapy under investigation, has been previously administered.
7. Papzimeos will not be authorized for patients:
 - a. Currently receiving another investigational or systemic immunotherapy for RRP
 - b. With prior or concurrent use of investigational gene, cell, or immunotherapy for RRP
 - c. With a history of severe adverse reaction to adenoviral or other viral vector-based therapies (e.g., anaphylaxis, cytokine release syndrome, severe systemic inflammatory response)

Pharmacy Management Drug Policy

Papzimeos™ (zopapogene imadenovec-drba)

POLICY GUIDELINES:

1. Utilization Management is contract dependent. Refer to specific contract/benefit language for exclusions.
 - a. Coverage criteria may be dependent on the contract renewal date.
 - b. Coverage of drugs listed in this policy are contract dependent.
 - c. Not all contracts/benefits allow coverage of healthcare professional administered drugs as part of their pharmacy benefit
 - d. Not all contracts/benefits cover all medical infusible drugs.
2. Clinical documentation must be submitted for each request (initial and recertification [if applicable]) unless otherwise specified (e.g., provider attestation required). Supporting documentation includes, but is not limited to, progress notes documenting previous treatments and treatment history, diagnostic testing, laboratory test results, genetic testing or biomarker results, imaging, and other objective or subjective measures of clinical benefit.
3. This policy does not apply to Medicare Part D and D-SNP pharmacy benefits. The drugs in this policy may apply to all other lines of business including Medicare Advantage.
4. For members with Medicare Advantage, medications with a National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) will be covered pursuant to the criteria outlined by the NCD and/or LCD. NCDs/LCDs for applicable medications can be found on the CMS website at <https://www.cms.gov/medicare-coverage-database/search.aspx>. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS permits a Medicare Advantage Organization (MAO) to establish its own coverage determinations in accordance with 42 CFR § 422.101(b)(6). Indications that have not been addressed by the applicable medication's LCD/NCD will be covered in accordance with criteria determined by the Health Plan. Step therapy requirements may be imposed in addition to LCD/NCD requirements.
5. Unless otherwise indicated within drug specific criteria, the drugs listed in this policy are administered by a healthcare professional and therefore are covered under the medical benefit.
6. All utilization management requirements outlined in this policy are compliant with applicable New York State insurance laws and regulations. Policies will be reviewed and updated as necessary to ensure ongoing compliance with all state and federally mandated coverage requirements.
7. This policy is based on available evidence as of the last review date. Coverage determinations are subject to applicable plan documents, state and federal regulations, and individual patient circumstances. This policy does not constitute medical advice.
8. For commercial contracts, medical necessity determinations align with the Certificate of Coverage issued by the Health Plan, which states that covered services must be clinically appropriate and not primarily for the convenience of the member, the member's family, or the provider.
9. This policy is subject to ongoing revision. Newly marketed drugs and existing drugs with new indications may be subject to prior authorization until formal coverage criteria are established. Inclusion of a drug in this policy does not guarantee its current availability on the market, as some agents may be discontinued, withdrawn, or otherwise unavailable. As product status changes, drugs may be removed from the policy.
10. Manufacturers may either discontinue participation in, or may not participate in, the Medicaid Drug Rebate Program (MDRP). Under New York State Medicaid requirements, physician-administered drugs must be produced by manufacturers that participate in the MDRP. Products made by manufacturers that do not participate in the MDRP will not be covered under Medicaid Managed Care/HARP lines of business. Drug coverage will not be available for any product from a non-participating manufacturer. For a complete list of New/Reinstated & Terminated Labelers please visit: <https://www.medicaid.gov/medicaid/prescriptiondrugs/medicaid-drug-rebate-program/newreinstated-terminated-labeler-information/index.html>

Pharmacy Management Drug Policy

Papzimeos™ (zopapogene imadenovec-drba)

11. The following applies to all gene and cellular therapies unless otherwise specified within the drug-specific coverage criteria:
- a. Administration, Retreatment, and Treatment with Additional or Other Gene/Cellular Therapies
 - i. One-Time Administration
 1. Most gene and cellular therapies, whether autologous, allogeneic (“off-the-shelf”), or in vivo gene-transfer therapies, are designed and studied as one-time treatments.
 2. Repeat dosing, reinfusion, or sequential therapy with other gene or cellular products has not been established as safe, effective, or clinically appropriate.
 - ii. Retreatment/Repeat Administration
 1. Retreatment with the same gene or cellular therapy product is considered experimental and investigational because:
 - a. Clinical trials evaluated these therapies as single-administration interventions
 - b. Safety, efficacy, and durability of a second administration have not been established
 - c. Risks of immune activation, insertional mutagenesis, or vector immunity may be increased with repeat dosing
 - iii. Treatment with an Additional or Other Gene/Cellular Therapy
 1. Treatment with an additional or different gene or cellular therapy after prior exposure to any gene or cellular therapy is also considered experimental and investigational, unless supported by evidence demonstrating (a-c):
 - a. Anticipated clinical benefit beyond available standard therapies
 - b. Safety of sequential administration
 - c. Justification for selecting a second gene/cellular intervention after a prior one
 2. This includes, but is not limited to:
 - a. Switching between CAR-T products (e.g., CD19 → CD19 or CD19 → BCMA)
 - b. Switching between autologous and allogeneic cellular therapies
 - c. Sequential use of CAR-T, TCR-T, NK-cell therapies, or other genetically engineered cell therapies
 - d. Receiving a gene therapy after previous gene or cellular therapy exposure
 - e. Receiving an in vivo gene therapy following any prior vector-based therapy
 - iv. Prior Gene/Cell Therapy Exposure
 1. An individual is generally not eligible for additional gene or cellular therapy if they have previously received:
 2. Any autologous cellular therapy (e.g., CAR-T, TCR-T, TIL),
 - a. Any allogeneic genetically modified cellular therapy,
 - b. Any in vivo gene therapy (e.g., AAV, lentiviral vector)
 - c. Any ex vivo gene-modified cell product
 - d. Are being considered for any other gene or cellular therapy without documented evidence supporting safety and anticipated benefit.
12. The requested site of care may impact approval timeframe and is subject to review.

CODES:

Eligibility for reimbursement is based upon the benefits set forth in the member’s subscriber contract. CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.

Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

Pharmacy Management Drug Policy

Papzimeos™ (zopapogene imadenovec-drba)

Code Key:

Experimental/Investigational = (E/I),

Not medically necessary/ appropriate = (NMN).

Copyright © 2006 American Medical Association, Chicago, IL

HCPCS:

J3590 (NOC) Papzimeos

UPDATES:

Date	Revision
06/12/2026	Revised
06/01/2026	Revised
01/16/2026	Effective & Posted
01/13/2026	Created
11/13/2025	P&T Committee Approval

REFERENCES:

1. Papzimeos [package insert]. Germantown, MD: Precigen. Inc.; Revised August 2025
2. Muroso S, Current treatment options for recurrent respiratory papillomatosis: A narrative review. *Auris Nasus Larynx*. 2025;52(4):307-313
3. Fortes HR, von Ranke FM, Escuissato DL, et al. Recurrent respiratory papillomatosis: A state-of-the-art review. *Respiratory Medicine*. 2017;126:116-121
4. Katsenos S, becker H. Recurrent respiratory papillomatosis: a rare chronic disease, difficult to treat, with potential to lung cancer transformation: apropos of two cases and a brief literature review. *Case Rep. Oncol*. 2011; 4(1):162-171
5. Norberg SM, Valdez J, Napoer S, et al. PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase I/II clinical trial. *Lancet Respir Med*. 2025;13(4)318-326
6. Karatayli- Ozgursoy S, Bishop JA, Hillel A, Akst L, Best SR. Risk Factors for Dysplasia in Recurrent Respiratory Papillomatosis in an Adult and Pediatric Population. *Ann Otol Rhinol Laryngol*. 2016;125(3):235-241.
7. NCT04724980. Adjuvant PRGN-2012 in adult patients with recurrent respiratory papillomatosis. National Library of Medicine. National Center for Biotechnology Information. Available at <https://www.clinicaltrials.gov/study/NCT04724980?intr=nct04724980&rank=1>. Accessed January 2, 2026.
8. Donne AJ, Keltie K, Bellios E, et al. Current Practice, Safety and Efficacy of Interventions for Recurrent Respiratory Papillomatosis: Evidence From a UK Registry. *Clin Otolaryngol*. 2025;50(2):271-279
9. Hock K, Kennedy A, Howell R, et al. Surgery and Adjuvant Therapy Improve Derkey Scores in Adult and Pediatric Respiratory Papillomatosis. *Laryngoscope*. 2022;132(12):2420-2426
10. Bertino G, Pedretti F, Mauramati S, et al. Recurrent Laryngeal papillomatosis: multimodal therapeutic strategies. Literature review and multicentre retrospective study. *ACTA Otorhinolaryngologica Italica*. 2023;43. DOI: [10.14639/0392-100X-suppl.1-43-2023-14](https://doi.org/10.14639/0392-100X-suppl.1-43-2023-14)

Pharmacy Management Drug Policy

Papzimeos™ (zopapogene imadenovec-drba)

Appendix:

Derkey Score

The Derkey Staging System is a severity scale used to quantify the severity of RPP and is based on the laryngeal structures involved. Derkey's score is composed of a for-site score and a clinical score. The for-site score takes into account the amount of disease (0: none surface; 2: raised; 3: bulky) in the different laryngeal and extra-laryngeal subsites. The clinical score takes into consideration voice quality, presence of stridor, urgency of intervention and presence of respiratory distress.¹⁰

STAGING ASSESSMENT FOR RECURRENT LARYNGEAL PAPILLOMATOSIS

PATIENTS INITIALS : _____ DATE OF SURGERY _____ SURGEON _____

PATIENT ID # _____ INSTITUTION _____

1. How long since the last papilloma surgery? _____ days _____ weeks _____ months
_____ years _____ don't know
_____ this is the child's first surgery

2. Counting today's surgery, how many papilloma surgeries in the past 12 months? _____

3. Describe the patient's voice today :
normal _____ (0) abnormal _____ (1) aphonic _____ (2)

4. Describe the patient's stridor today :
absent _____ (0) present with activity _____ (1) present at rest _____ (2)

5. Describe the urgency of today's intervention :
scheduled _____ (0) elective _____ (1) urgent _____ (2) emergent _____ (3)

6. Describe today's level of respiratory distress :
none _____ (0) mild _____ (1) mod _____ (2) severe _____ (3) extreme _____ (4)

Total score of questions 3 – 6 = _____

FOR EACH SITE, SCORE AS: 0=NONE, 1 – SURFACE LESION, 2 – RAISED LESION, 3 – BULKY LESION

LARYNX

Epiglottis

Lingual surface _____ Laryngeal surface _____

Aryepiglottic folder : Right _____ Left _____

False vocal cords : Right _____ Left _____

True vocal cords : Right _____ Left _____

Arytenoids : Right _____ Left _____

Anterior commissure _____ Posterior commissure _____

Subglottis _____

TRACHEA :

Upper one-third _____

Middle one-third _____

Lower one-third _____

Bronchi : Right _____ Left _____

Tracheotomy stoma _____

OTHER :

Nose _____

Palate _____

Pharynx _____

Esophagus _____

Lungs _____

Other _____

TOTAL SCORE ALL SITES : _____ **TOTAL CLINICAL SCORE :** _____

Pharmacy Management Drug Policy

Papzimeos™ (zopapogene imadenovec-drba)

Voice Handicap Index-10 (VHI-10)

The VHI-10 is a validated self-assessment tool designed to quantify the psychosocial impact of voice disorders on patients. It evaluates perceived handicap associated with dysphonia by capturing functional, physical and emotional aspects through a concise questionnaire consisting of 10 items. Each item is rated on a 5-point Likert scale from 0 (never) to 4 (always), allowing for a total score between 0 and 40 with higher scores indicating a greater perceived voice handicap. A score above 11 typically suggests a significant voice disorder requiring clinical attention.

Voice Handicap Index (VHI)-10

Instructions: These are statements that many people have used to describe their voices and the effects of their voices on their lives. Circle the response that indicates how frequently you have the same experience.

	0-Never	1-Almost Never	2-Sometimes	3-Almost Always	4-Always
• My voice makes it difficult for people to hear me.	0	1	2	3	4
• People have difficulty understanding me in a noisy room.	0	1	2	3	4
• My voice difficulties restrict personal and social life.	0	1	2	3	4
• I feel left out of conversations because of my voice.	0	1	2	3	4
• My voice problem causes me to lose income.	0	1	2	3	4
• I feel as though I have to strain to produce voice.	0	1	2	3	4
• The clarity of my voice is unpredictable.	0	1	2	3	4
• My voice problem upsets me.	0	1	2	3	4
• My voice makes me feel handicapped.	0	1	2	3	4
• People ask, "What's wrong with your voice?"	0	1	2	3	4

Rosen, CA. et al. Development and Validation of the Voice Handicap Index-10. *Laryngoscope* 2004; 114: 1549-56.